




SUPPLEMENTAL MATERIAL


FIGURES



C.



D.






Figure I. SD or JCR rats were sacrificed on day 0, 3, 6 or 9 of RI. Tissue samples were collected from the NZ or the CZ. Pro and active MMP1 (A), MMP3 (B), MMP7 (C), MMP13 (D) and MMP14 (MT1-MMP) (E) expression were determined by Western Blot in SD (left) and JCR (right) rats. Top: Representative Western blot using anti-MMP1, anti-MMP3, anti-MMP7, anti-MMP13 and anti-MMP14 antibodies. Bottom: Cumulative data, * p<0.05 vs. day 0 RI, † p<0.05 vs. SD, n=5.




Figure II. A. JCR rats were treated different concentrations of the MMP12 inhibitor as indicated and underwent 10 days of RI. Tissue samples were collected from the NZ and the CZ. Pro and active MMP12 and MMP8 expression were determined by Western Blot. Top: Representative Western blots detecting pro and active forms of MMP12 and MMP8 in the CZ. Bottom: Cumulative data in the CZ. **B.** Same as A except rats were treated with the MMP8 inhibitor. n=2.




Figure III. SD or JCR rats were sacrificed on day 0, 3, 6 or 9 of RI. Serum samples were collected. Pro and active MMP12 expression were determined by Western Blot in SD (left) and JCR (right) rats. Top: Representative Western blot using anti-MMP12 antibodies. Bottom: Cumulative data, *p<0.05 vs. day 0 RI, †p<0.05 vs. SD, n=5.




Figure IV. SD or JCR lean rats were sacrificed on day 10 of RI. Coronary blood flow was measured in the CZ and the NZ using microspheres during LAD occlusion and is expressed as the ratio between CZ and NZ flows at day 10 of RI. *p<0.05 vs. day 0 RI, †p<0.05 vs. SD, n=5.